An individualized mRNA neoantigen therapy plus Keytruda cut the risk of recurrence or death versus Keytruda alone in 1,137 patients with completely resected stage IIB-IV melanoma, according to a prespecified interim analysis of the Phase III INTerpath-001 trial. Merck and Moderna also said the combo significantly improved recurrence-free survival and distant metastasis-free survival, setting up potential regulatory filings.

Why It Matters To Oncology

• The result is one of the clearest late-stage validations yet for personalized mRNA cancer vaccines in the adjuvant setting.

• INTerpath-001 tested intismeran autogene (V940/mRNA-4157), which is built from each patient's tumor mutational signature to generate a tailored antitumor immune response.

• For clinicians, the readout suggests a possible new post-resection option for high-risk melanoma beyond PD-1 monotherapy.

• Safety was reported as consistent with prior studies of the regimen.

The Financials

• Merck shares rose 8% in premarket trading Wednesday, while Moderna surged 91%.

• Barclays analysts have estimated intismeran could generate roughly $3 billion in melanoma sales by 2035.

• The positive Phase III readout strengthens the commercial case for expanding the platform across additional tumor types.

What They're Saying

• Moderna CEO Stéphane Bancel called the findings “a pivotal moment for the field of cancer research.”

• Principal investigator Georgina Long said the data mark “a landmark moment for adjuvant melanoma treatment,” with potential to establish a new treatment paradigm.

• Merck oncology executive Jane Healy said side effects were similar to those seen with other vaccines.

What's Next

• The trial will continue to assess other secondary endpoints, including overall survival.

• Merck and Moderna said the data will be presented at a future medical meeting and shared with regulators.

• The broader INTerpath program includes nine Phase II and III studies across melanoma, non-small-cell lung cancer, bladder cancer and renal cell carcinoma.